243 related articles for article (PubMed ID: 16400826)
1. Immunobiology of oligodendrocytes in multiple sclerosis.
Ruffini F; Chojnacki A; Weiss S; Antel JP
Adv Neurol; 2006; 98():47-63. PubMed ID: 16400826
[No Abstract] [Full Text] [Related]
2. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis.
Vanderlocht J; Hellings N; Hendriks JJ; Vandenabeele F; Moreels M; Buntinx M; Hoekstra D; Antel JP; Stinissen P
J Neurosci Res; 2006 Apr; 83(5):763-74. PubMed ID: 16477612
[TBL] [Abstract][Full Text] [Related]
3. [Pathogenesis of multiple sclerosis: status of research].
Hartung HP
Wien Med Wochenschr; 1996; 146(19-20):520-7. PubMed ID: 9082652
[TBL] [Abstract][Full Text] [Related]
4. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
Taoufik E; Tseveleki V; Euagelidou M; Emmanouil M; Voulgari-Kokota A; Haralambous S; Probert L
Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
[TBL] [Abstract][Full Text] [Related]
5. Studies of autoimmunity in multiple sclerosis.
Whitaker JN; Snyder DS
CRC Crit Rev Clin Neurobiol; 1984; 1(1):45-82. PubMed ID: 6400508
[TBL] [Abstract][Full Text] [Related]
6. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis.
van Noort JM; van Sechel AC; Bajramovic JJ; el Ouagmiri M; Polman CH; Lassmann H; Ravid R
Nature; 1995 Jun; 375(6534):798-801. PubMed ID: 7596414
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis.
Dhib-Jalbut S
Neurology; 2007 May; 68(22 Suppl 3):S13-21; discussion S43-54. PubMed ID: 17548563
[TBL] [Abstract][Full Text] [Related]
8. Remembering MOG: autoantibody mediated demyelination in multiple sclerosis?
Wekerle H
Nat Med; 1999 Feb; 5(2):153-4. PubMed ID: 9930860
[No Abstract] [Full Text] [Related]
9. To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis.
Schirmer L; Srivastava R; Hemmer B
Mult Scler; 2014 Mar; 20(3):271-9. PubMed ID: 24589684
[TBL] [Abstract][Full Text] [Related]
10. The oligodendroglial cell: biology and immunology and relationship to multiple sclerosis.
Bartlett PF; Mackay IR
J Clin Lab Immunol; 1983 May; 11(1):1-7. PubMed ID: 6348293
[TBL] [Abstract][Full Text] [Related]
11. [Multiple sclerosis. Biomarkers for deciding treatment].
Meinl E; Voltz R
MMW Fortschr Med; 2004 May; 146 Spec No 2():57-8. PubMed ID: 15376703
[No Abstract] [Full Text] [Related]
12. Multiple sclerosis. Presenting an odd autoantigen.
Steinman L
Nature; 1995 Jun; 375(6534):739-40. PubMed ID: 7541112
[No Abstract] [Full Text] [Related]
13. Dynamic changes of apoptosis-inducing ligands and Th1/Th2 like subpopulations in Hantaan virus-induced hemorrhagic fever with renal syndrome.
Liu JM; Zhu Y; Xu ZW; Ouyang WM; Wang JP; Liu XS; Cao YX; Li Q; Fang L; Zhuang R; Yang AG; Jin BQ
Clin Immunol; 2006 Jun; 119(3):245-51. PubMed ID: 16616877
[TBL] [Abstract][Full Text] [Related]
14. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
Butzkueven H; Emery B; Cipriani T; Marriott MP; Kilpatrick TJ
Glia; 2006 May; 53(7):696-703. PubMed ID: 16498619
[TBL] [Abstract][Full Text] [Related]
15. Eradication of established tumors in mice by a combination antibody-based therapy.
Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
[TBL] [Abstract][Full Text] [Related]
16. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma.
Tian JQ; Wang ZP; Rodriguez R; Fu JS; Lu JZ; Ma BL
Urology; 2006 May; 67(5):1093-8. PubMed ID: 16635513
[TBL] [Abstract][Full Text] [Related]
17. Antiapoptotic signaling by a remyelination-promoting human antimyelin antibody.
Howe CL; Bieber AJ; Warrington AE; Pease LR; Rodriguez M
Neurobiol Dis; 2004 Feb; 15(1):120-31. PubMed ID: 14751777
[TBL] [Abstract][Full Text] [Related]
18. Evidence for pathogenic heterogeneity in multiple sclerosis.
Lucchinetti CF; Bruck W; Lassmann H
Ann Neurol; 2004 Aug; 56(2):308. PubMed ID: 15293289
[No Abstract] [Full Text] [Related]
19. Effects of interferon-beta on oligodendroglial cells.
Heine S; Ebnet J; Maysami S; Stangel M
J Neuroimmunol; 2006 Aug; 177(1-2):173-80. PubMed ID: 16753226
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination.
Storch MK; Piddlesden S; Haltia M; Iivanainen M; Morgan P; Lassmann H
Ann Neurol; 1998 Apr; 43(4):465-71. PubMed ID: 9546327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
